| Literature DB >> 30181442 |
Magda Kondej1, Agata Bartyzel2, Monika Pitucha3, Tomasz M Wróbel4,5, Andrea G Silva6, Dariusz Matosiuk7, Marián Castro8, Agnieszka A Kaczor9,10.
Abstract
CompoundEntities:
Keywords: X-ray studies; dopamine D2 receptor; dopamine D2 receptor antagonist; molecular modeling; thermal studies
Mesh:
Substances:
Year: 2018 PMID: 30181442 PMCID: PMC6225423 DOI: 10.3390/molecules23092249
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The investigated compound D2AAK1_3 as a modification of the lead structure D2AAK1.
Scheme 1Synthesis of D2AAK1_3.
Figure 2Competition binding curve for D2AAK1_3 at human D2 receptors. Displacement of the specific binding of the radioligand [3H]Spiperone by D2AAK1_3 in membranes from CHO-K1 cells stably expressing human cloned D2 receptors. Haloperidol was used as the reference compound in these assays. The graph shows the results (mean ± SEM) from a single experiment representative of 2 independent experiments performed in duplicate.
Figure 3Molecular structures with atom numbering scheme of D2AAK1_3. Displacement ellipsoids are shown at the 30% probability level.
Crystal data and structure refinement of D2AAK1_3.
| Formula | C22H24N2O |
| Formula weight | 332.43 |
| Temperature K | 293(2) |
| Crystal system | orthorhombic |
| Space group | |
| a (Å) | 5.9600(4) |
| b (Å) | 15.0986(9) |
| c (Å) | 16.1571(9) |
| Volume (Å3) | 1814.5(2) |
| Z | 4 |
| Calculated density (g cm−3) | 1.217 |
| μ (mm−1) | 0.075 |
| Absorption correction | multi-scan |
| F(000) | 712 |
| Crystal size (mm) | 0.50 × 0.20 × 0.20 |
| θ range (°) | 2.698 to 27.103 |
| Index ranges | −7 ≤ h ≤ 7 |
| Reflections collected/unique | 14,278/3993 |
| Rint | 0.0442 |
| Data/restraints/parameters | 3993/0/231 |
| GooF on F2 | 1.000 |
| Final R indices[I > 2σ(I)] | R1 = 0.0437, wR2 = 0.0887 |
| R indices(all data) | R1 = 0.0745, wR2 = 0.1019 |
| Largest diff. peak/hole, e Å−3 | 0.156/−0.111 |
Interatomic distances and selected bond angles.
|
| |||
| C1-N1 | 1.359(3) | C10-C11 | 1.364(5) |
| C1-C2 | 1.369(3) | C11-C12 | 1.376(4) |
| C2-C15 | 1.441(3) | C13-N2 | 1.462(3) |
| C2-C3 | 1.465(3) | C13-C14 | 1.497(3) |
| C3-C14 | 1.325(3) | C15-C22 | 1.406(3) |
| C3-C4 | 1.506(3) | C15-C16 | 1.409(3) |
| C4-C5 | 1.512(3) | C16-C17 | 1.373(4) |
| C5-N2 | 1.459(3) | C17-O1 | 1.380(3) |
| C6-N2 | 1.472(3) | C17-C20 | 1.392(4) |
| C6-C7 | 1.503(3) | C18-O1 | 1.416(3) |
| C7-C8 | 1.376(3) | C18-C19 | 1.493(4) |
| C7-C12 | 1.383(3) | C20-C21 | 1.366(4) |
| C8-C9 | 1.379(4) | C21-C22 | 1.386(4) |
| C9-C10 | 1.360(4) | C22-N1 | 1.376(3) |
|
| |||
| C14-C3-C2 | 124.6(2) | C3-C14-C13 | 124.1(2) |
| C14-C3-C4 | 118.6(2) | C16-C17-O1 | 124.3(2) |
| C2-C3-C4 | 116.7(2) | O1-C17-C20 | 114.6(2) |
| C3-C4-C5 | 113.0 (2) | C5-N2-C13 | 108.4(2) |
| N2-C5-C4 | 111.0(2) | C5-N2-C6 | 111.2(2) |
| N2-C6-C7 | 114.1(2) | C13-N2-C6 | 107.7(2) |
| N2-C13-C14 | 113.1(2) | C17-O1-C18 | 118.0(2) |
|
| |||
| C4-C5-N2-C13 | −65.0(3) | C4-C3-C14-C13 | 0.6(4) |
| C3-C4-C5-N2 | 47.6(3) | N2-C13-C14-C3 | −18.2(4) |
| C14-C3-C4-C5 | −15.0(3) | C14-C13-N2-C5 | 49.2(3) |
Hydrogen bonding and C-H···Cg interactions geometry.
|
| ||||
|
|
|
|
|
|
| N1-H1N···N2 i | 0.88(3) | 2.41(3) | 3.217(3) | 154(2) |
|
| ||||
|
|
|
|
|
|
| C4-H4B··· | 0.97 | 2.94 | 3.567(3) | 124 |
| C19-H19C··· | 0.96 | 3.00 | 3.799(3) | 142 |
Symmetry codes: (i) x − 1/2, −y + 1/2, −z + 1; (ii) x − 1/2, −y + 1/2, −z + 1; (iii) x + 1, y, z; Cg1 and Cg4 are the centroids of the N1/C1/C2/C15/C22 and C15/C16/C17/C20/C21/C22 rings, respectively.
Figure 4Fragment of the crystal structure of D2AAK1_3 showing formation of one-dimensional columns viewed along the a-axis.
Figure 5The lead structure D2AAK1 (A,B) and its derivative D2AAK1_3 (C,D) in the binding pocket of human dopamine D2 receptor. (A,C) 3D view of the binding site. Ligands represented as sticks with magenta carbon atoms. Protein represented as wire with grey carbon atoms, main interacting residues shown as sticks. Hydrogen bonds shown as yellow dashed lines. Non-polar hydrogen atoms not shown for clarity. (B,D) 2D view of the binding site.
Figure 6Changes in potential energy (A) and ligand RMSD (B) during 100 ns molecular dynamics simulations for D2AAK1_3 in complex with human dopamine D2 receptor.
Figure 7Molecular interactions of D2AAK1_3 with human dopamine D2 receptor during 100 ns molecular dynamics simulations. (A) histogram of interactions. The stacked bar charts are normalized over the course of the trajectory: For example, a value of 0.7 suggests that 70% of the simulation time the specific interaction is maintained. Values over 1.0 are possible as some protein residue may make multiple contacts of same subtype with the ligand. (B) summary of contacts. Interactions that occur more than 30.0% of the simulation time in the selected trajectory (0.00 through 100.00 ns), are shown.
Figure 8(A) TG, DTG and DSC curves of the studied compound recorded in air atmosphere using cylindrical shape crucible; (B) TG and DTG curves of the studied compound recorded in air atmosphere using used flat platinum plate (heating rate 10 °C min−1).
Figure 9TG and DTG curves of D2AAK1_3 recording during thermal analysis with heating rate 20 °C min−1 in air (A) and N2 (B) atmospheres.
Figure 103D diagram of FTIR spectrum of gases evolved during thermal decomposition D2AAK1_3 in air (A) and nitrogen (B) atmospheres.
Figure 11FTIR spectrum of volatile products of thermal decomposition of D2AAK1_3 recorded at 398 °C in inert atmosphere and the spectra of toluene, piperidine and indole.
Scheme 2The thermal behavior of compounds in air and N2 atmospheres (heating rate 20 °C min−1).